Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial
Authors
Keywords
-
Journal
BLOOD
Volume 137, Issue 7, Pages 877-887
Publisher
American Society of Hematology
Online
2020-11-13
DOI
10.1182/blood.2020008727
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
- (2020) Michael Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- BCL2-Family Dysregulation in B-Cell Malignancies: From Gene Expression Regulation to a Targeted Therapy Biomarker
- (2019) Benoît Tessoulin et al. Frontiers in Oncology
- BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models
- (2019) Xiaohong Zhao et al. CANCER CELL
- Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma
- (2019) Liang Zhang et al. Science Translational Medicine
- Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
- (2018) Constantine S. Tam et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first line treatment of older patients with mantle cell lymphoma
- (2018) Rémy Gressin et al. HAEMATOLOGICA
- Dynamic molecular monitoring reveals that SWI–SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma
- (2018) Rishu Agarwal et al. NATURE MEDICINE
- Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
- (2017) Matthew S. Davids et al. JOURNAL OF CLINICAL ONCOLOGY
- Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma
- (2017) Steven Le Gouill et al. NEW ENGLAND JOURNAL OF MEDICINE
- Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma
- (2017) Xiaohong Zhao et al. Nature Communications
- Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma
- (2016) D. Chiron et al. BLOOD
- High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma
- (2015) M.-H. Delfau-Larue et al. BLOOD
- Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma
- (2015) David Chiron et al. Oncotarget
- bcrm: Bayesian Continual Reassessment Method Designs for Phase I Dose-Finding Trials
- (2015) Michael Sweeting et al. Journal of Statistical Software
- Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma
- (2014) D. Chiron et al. Cancer Discovery
- Pharmacological and genomic profiling identifies NF-κB–targeted treatment strategies for mantle cell lymphoma
- (2013) Rami Rahal et al. NATURE MEDICINE
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
- (2013) Michael L. Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment of Older Patients with Mantle-Cell Lymphoma
- (2012) H.C. Kluin-Nelemans et al. NEW ENGLAND JOURNAL OF MEDICINE
- A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
- (2007) E. Hoster et al. BLOOD
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation